[{"id":"2dee9945-f549-4f20-8162-2f885a4bbaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887492","created_at":"2023-06-02T14:06:23.752Z","updated_at":"2025-02-25T13:49:51.075Z","phase":"Phase 1/2","brief_title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","source_id_and_acronym":"NCT05887492","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • TNG260"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"bc1b58c1-b1d8-4700-b8ba-84e1753bb5a8","acronym":"PRECEDE","url":"https://clinicaltrials.gov/study/NCT04970056","created_at":"2021-07-21T13:52:39.762Z","updated_at":"2025-02-25T15:26:58.339Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Consortium","source_id_and_acronym":"NCT04970056 - PRECEDE","lead_sponsor":"Arbor Research Collaborative for Health","biomarkers":" BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 09/18/2020","start_date":" 09/18/2020","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-11"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"8bd4b6dd-9110-48f1-9cd7-f15472829753","acronym":"","url":"https://clinicaltrials.gov/study/NCT02642042","created_at":"2021-01-18T12:51:12.920Z","updated_at":"2025-02-25T16:36:42.163Z","phase":"Phase 2","brief_title":"Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02642042","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • TP53 • STK11","pipe":" | ","alterations":" TP53 mutation • KRAS mutation","tags":["KRAS • TP53 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • docetaxel • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/18/2016","start_date":" 07/18/2016","primary_txt":" Primary completion: 05/15/2019","primary_completion_date":" 05/15/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"f4760edc-575b-4a03-b52a-92d92e44dfde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02371135","created_at":"2021-01-18T11:17:42.064Z","updated_at":"2025-02-25T16:51:29.235Z","phase":"","brief_title":"Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","source_id_and_acronym":"NCT02371135","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"aba33b5e-2046-4e2a-9fb8-ed489862ca5d","acronym":"NAUTIC","url":"https://clinicaltrials.gov/study/NCT06494540","created_at":"2025-02-25T17:53:16.413Z","updated_at":"2025-02-25T17:53:16.413Z","phase":"","brief_title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","source_id_and_acronym":"NCT06494540 - NAUTIC","lead_sponsor":"AstraZeneca","biomarkers":" KRAS • STK11","pipe":" | ","alterations":" KRAS mutation • STK11 mutation","tags":["KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-01-29"},{"id":"d934aafe-bd3e-4728-955c-fb7a4b80ce12","acronym":"HRPCa-II","url":"https://clinicaltrials.gov/study/NCT05333432","created_at":"2022-04-19T23:53:47.960Z","updated_at":"2025-02-25T17:37:45.989Z","phase":"","brief_title":"Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer","source_id_and_acronym":"NCT05333432 - HRPCa-II","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-28"},{"id":"0722b240-7848-480e-91ab-a7a7c502ac66","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445843","created_at":"2022-07-06T14:54:25.537Z","updated_at":"2024-07-02T16:34:27.361Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression \u003c 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","source_id_and_acronym":"NCT05445843","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • KRAS • STK11","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression","tags":["PD-L1 • KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 11/02/2026","primary_completion_date":" 11/02/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-06-11"},{"id":"b28a300d-a648-41cb-b9b3-e37a6c33dd25","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT04173507","created_at":"2021-01-18T20:21:36.422Z","updated_at":"2024-07-02T16:34:59.352Z","phase":"Phase 2","brief_title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","source_id_and_acronym":"NCT04173507 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Talzenna (talazoparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/14/2020","start_date":" 02/14/2020","primary_txt":" Primary completion: 11/24/2021","primary_completion_date":" 11/24/2021","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"1fffbecc-9d1d-4405-aa75-3725ff51616b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807048","created_at":"2023-04-10T14:03:23.661Z","updated_at":"2024-07-02T16:35:07.816Z","phase":"Phase 2","brief_title":"Daratumumab in STK11 Mutated NSCLC","source_id_and_acronym":"NCT05807048","lead_sponsor":"NYU Langone Health","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-24"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"2a7e1b59-835a-4e99-a8e3-f032d1fbcea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06341660","created_at":"2024-04-02T19:41:50.555Z","updated_at":"2024-07-02T16:35:12.061Z","phase":"Phase 2","brief_title":"To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06341660","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" STK11","pipe":"","alterations":" ","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/25/2023","start_date":" 05/25/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-02"},{"id":"2d710c27-775a-4a1c-8ecc-66ce86c200a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06331650","created_at":"2024-03-26T16:40:01.835Z","updated_at":"2024-07-02T16:35:12.792Z","phase":"Phase 2","brief_title":"A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06331650","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" STK11","pipe":"","alterations":" ","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-26"},{"id":"107dd190-b738-4816-b39c-d6828e427b79","acronym":"PancreasScan","url":"https://clinicaltrials.gov/study/NCT05006131","created_at":"2021-08-16T17:54:43.106Z","updated_at":"2024-07-02T16:35:13.981Z","phase":"","brief_title":"Pancreatic Cancer Screening for At-risk Individuals","source_id_and_acronym":"NCT05006131 - PancreasScan","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/10/2027","primary_completion_date":" 03/10/2027","study_txt":" Completion: 03/10/2028","study_completion_date":" 03/10/2028","last_update_posted":"2024-03-19"},{"id":"4a225605-ea40-4786-bbe9-47b89ed77c1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234307","created_at":"2022-02-10T13:52:54.502Z","updated_at":"2024-07-02T16:35:14.388Z","phase":"Phase 1","brief_title":"PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05234307","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1 • ALK • STK11","pipe":"","alterations":" ","tags":["PD-L1 • ALK • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • PBF-1129"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"942c232f-7333-4f3f-b161-29ff99678077","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122896","created_at":"2023-11-08T22:13:14.798Z","updated_at":"2024-07-02T16:35:17.268Z","phase":"Phase 1","brief_title":"Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","source_id_and_acronym":"NCT06122896","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 11/21/2023","start_date":" 11/21/2023","primary_txt":" Primary completion: 10/31/2040","primary_completion_date":" 10/31/2040","study_txt":" Completion: 10/31/2041","study_completion_date":" 10/31/2041","last_update_posted":"2024-02-28"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"277f8fcd-b41c-46ce-afa0-e0dbc651dba0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06045572","created_at":"2023-09-21T15:10:54.497Z","updated_at":"2024-07-02T16:35:18.031Z","phase":"","brief_title":"Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer","source_id_and_acronym":"NCT06045572","lead_sponsor":"Galzu Institute of Research, Teaching, Science and Applied Technology","biomarkers":" TP53 • BRCA1 • PTEN • STK11 • S100P","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • TP53 expression","tags":["TP53 • BRCA1 • PTEN • STK11 • S100P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • TP53 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-02-22"}]